Fierce Pharma3h
Merck's Winrevair slashes mortality-morbidity risk by 76%
The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...
Managed Healthcare Executive3h
Winrevair Reduced Risk of Morbidity and Mortality by 76% in PAH | ACC 2025
In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension ...
Pulmonary Hypertension News3h
FDA decision on Yutrepia for PAH and PH-ILD due on May 24
The FDA is poised to issue a final decision on the approval and marketing of Yutrepia, an inhaled dry powder formulation of ...